Feb 15, 2013 by Brian Orelli, PhDWill There Ever Be an Obesity Drug Blockbuster?Insurers are likely the key to overcome lazy patients.
Feb 14, 2013 by Brian Orelli, PhDPeregrine's Epic Failure (Maybe)Peregrine Pharmaceuticals releases phase 2 data on bavituximab in pancreatic cancer without any p-values.
Feb 13, 2013 by Brian Orelli, PhDStem Cells Have a Long Way to GoStemCells produces tantalizing data on its neural stem cell product HuCNS-SC, but don't read too much into it.
Feb 12, 2013 by Brian Orelli, PhDWe Love You, Just Not Enough to Buy You (Yet)Regeneron says Sanofi plans to buy more shares, but not the entire company.
Feb 9, 2013 by Brian Orelli, PhDEasy, Peasy, Just "Pick Winners" Amgen's new strategy has a silly name, but it's a decent plan none the less.
Feb 9, 2013 by Brian Orelli, PhDEasy, Peasy, Just "Pick Winners" Amgen's new strategy has a silly name, but it's a decent plan none the less.
Feb 8, 2013 by Brian Orelli, PhDA Generic Double WhammyTeva's sales are hurt by generic competition and lost sales of its own generics.
Feb 7, 2013 by Brian Orelli, PhDIf You're Going to Fail, Fail QuicklyEli Lilly drops development of tabalumab for rheumatoid arthritis.
Feb 6, 2013 by Brian Orelli, PhDA Win-Win Multiple Sclerosis Deal?Elan sells its share of Tysabri to partner Biogen-Idec.
Feb 6, 2013 by Brian Orelli, PhDWho's Going to Buy This Orphan Drugmaker?Protalix is exploring its options.
Feb 5, 2013 by Brian Orelli, PhDGuilty Until Proven InnocentIdenix drops development of IDX184 and IDX19368.
Feb 4, 2013 by Brian Orelli, PhDPiling on the Phase 3 DataGilead releases data from two more phase 3 trials for its hepatitis C treatment sofosbuvir.
Feb 4, 2013 by Brian Orelli, PhDThe Medicines Company Licenses Alnylam's Cholesterol ProgramAlnylam gets $25 million upfront with the potential for $180 million in milestones and double-digit royalties.
Feb 1, 2013 by Brian Orelli, PhDDelayed RecoveryMerck delays filing for approval of its osteoporosis drug odanacatib.
Jan 31, 2013 by Brian Orelli, PhDTwo Peas in a Pharma PodPfizer's and Bristol-Myers Squibb's fates are tied to blood thinner Eliquis.
Jan 31, 2013 by Brian Orelli, PhDA Reacquired Drug Lottery TicketSpectrum reacquires the rights to apaziquone from Allergan.
Jan 31, 2013 by Brian Orelli, PhDFalling Revenue? Who Cares!Vertex's potential trumps current sales projections.
Jan 31, 2013 by Brian Orelli, PhDMake Money From Alzheimer's Disease Whether Drugs Succeed or NotA look at Alzheimer's diagnostics.
Jan 30, 2013 by Brian Orelli, PhDIsis: Antisense Lives (Again)!Isis gets its first next-generation antisense drug, Kynamro, approved by the FDA.
Jan 28, 2013 by Brian Orelli, PhDPartner = Buyout? Not So Fast.Idenix partners up IDX719 with J&J's hepatitis C compounds.
